Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 4, 2000, Pages 1108-1111

  Ernst, Erika J ^a,b   Klepser, Michael E ^a   Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC; POLYENES;

EID: 0034102140     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.4.1108-1111.2000     Document Type: Article

References (12)

1. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
2. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, 4th ed Williams & Wilkins, Baltimore, Md.
3. Ernst, E. J., M. E. Kiepser, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 33:75-80.
4. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn. Microbiol. Infect. Dis. 26:125-131.
5. Klepser, M. E., E. J. Ernst, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1998. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob. Agents Chemother. 42:1387-1391.
6. Klepser, M. E., E. J. Ernst, M. E. Ernst, and M. A. Pfaller. 1997. Growth medium effect on the antifungal activity of LY 303366. Diagn. Microbiol. Infect. Dis. 29:227-231.
7. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
8. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
9. Klepser, M. E., E. J. Wolfe, and M. A. Pfaller. 1998. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J. Antimicrob. Chemother. 41:397-401.
10. Minguez, F., M. L. Chiu, J. E. Lima, R. Nique, and J. Prieto. 1994. Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. J. Antimicrob. Chemother. 34:93-100.
11. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Turnidge, J. D., S. Gudmundsson, B. Vogelman, and W. A. Craig. 1994. The postantihiotic effect of antifungal agents against common pathogenic yeasts. J. Antimicrob. Chemother. 34:83-92.